<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219114</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-IPH-DUM-2010/1</org_study_id>
    <nct_id>NCT01219114</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use</brief_title>
  <official_title>A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions
      of actual use in patients who are diagnosed with complicated Skin and Skin Structure
      infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are
      prescribed CUBICIN by their physician.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Inability to recruit patients within the specified time period. No patients have been enrolled
    in the study.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events observed during the treatment duration</measure>
    <time_frame>Ranges from during treatment and up to 14 days after last administration of daptomycin (follow up)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response determined by cure rate</measure>
    <time_frame>Ranges from during treatment and up to 14 days after last administration of daptomycin</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        several private and government tertiary hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cSSSI known or suspected to be due to gram-positive bacteria

          -  Diagnosis of right-sided endocarditis with one or more positive culture for S. aureus
             within two days prior to initiation of medication

          -  Prescribed daptomycin by patient's attending physician

        Exclusion Criteria:

          -  Known allergic or serious adverse reaction to daptomycin

          -  Patients with pneumonia

          -  Patients with baseline CPK values &gt;1000 U/L or 5x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milagros Tan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Philippines</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Arca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Philippines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <state>Davao</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <state>Iloilo</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasig City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2010</study_first_submitted>
  <study_first_submitted_qc>October 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>September 27, 2011</last_update_submitted>
  <last_update_submitted_qc>September 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Daptomycin</keyword>
  <keyword>endocarditis</keyword>
  <keyword>complicated skin and skin structure infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

